Assetmark Inc. boosted its holdings in shares of Amphastar Pharmaceuticals, Inc. (NASDAQ:AMPH – Free Report) by 6.2% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 29,673 shares of the company’s stock after purchasing an additional 1,727 shares during the quarter. Assetmark Inc. owned about 0.06% of Amphastar Pharmaceuticals worth $1,113,000 as of its most recent SEC filing.
A number of other hedge funds also recently bought and sold shares of AMPH. Juncture Wealth Strategies LLC grew its holdings in shares of Amphastar Pharmaceuticals by 74.3% in the first quarter. Juncture Wealth Strategies LLC now owns 21,453 shares of the company’s stock worth $804,000 after purchasing an additional 9,148 shares during the last quarter. Summit Global Investments grew its holdings in shares of Amphastar Pharmaceuticals by 26.4% in the first quarter. Summit Global Investments now owns 37,300 shares of the company’s stock worth $1,399,000 after purchasing an additional 7,800 shares during the last quarter. Royce & Associates LP bought a new position in shares of Amphastar Pharmaceuticals in the first quarter worth about $837,000. Los Angeles Capital Management LLC grew its holdings in shares of Amphastar Pharmaceuticals by 164.8% in the first quarter. Los Angeles Capital Management LLC now owns 26,475 shares of the company’s stock worth $993,000 after purchasing an additional 16,475 shares during the last quarter. Finally, Granite Investment Partners LLC bought a new position in shares of Amphastar Pharmaceuticals in the first quarter worth about $20,131,000. Hedge funds and other institutional investors own 62.49% of the company’s stock.
Amphastar Pharmaceuticals Stock Performance
Shares of Amphastar Pharmaceuticals stock opened at $53.40 on Friday. Amphastar Pharmaceuticals, Inc. has a 52 week low of $26.76 and a 52 week high of $67.66. The company has a quick ratio of 2.88, a current ratio of 3.86 and a debt-to-equity ratio of 0.13. The firm has a market capitalization of $2.58 billion, a P/E ratio of 31.68 and a beta of 0.82. The company has a 50 day moving average price of $56.15 and a 200 day moving average price of $43.74.
Wall Street Analyst Weigh In
Several brokerages have issued reports on AMPH. Jefferies Financial Group began coverage on shares of Amphastar Pharmaceuticals in a report on Tuesday, July 25th. They set a “buy” rating and a $70.00 target price on the stock. Piper Sandler increased their target price on shares of Amphastar Pharmaceuticals from $66.00 to $71.00 in a report on Wednesday. Finally, StockNews.com upgraded shares of Amphastar Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Wednesday, June 21st.
Check Out Our Latest Research Report on AMPH
Insider Transactions at Amphastar Pharmaceuticals
In other news, Director Floyd F. Petersen sold 5,000 shares of the firm’s stock in a transaction that occurred on Wednesday, May 17th. The shares were sold at an average price of $43.13, for a total transaction of $215,650.00. Following the sale, the director now owns 80,117 shares of the company’s stock, valued at approximately $3,455,446.21. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Amphastar Pharmaceuticals news, CFO William J. Peters sold 36,868 shares of the firm’s stock in a transaction on Thursday, June 15th. The stock was sold at an average price of $50.85, for a total value of $1,874,737.80. Following the transaction, the chief financial officer now owns 105,603 shares in the company, valued at approximately $5,369,912.55. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, Director Floyd F. Petersen sold 5,000 shares of the firm’s stock in a transaction on Wednesday, May 17th. The shares were sold at an average price of $43.13, for a total value of $215,650.00. Following the completion of the transaction, the director now owns 80,117 shares in the company, valued at approximately $3,455,446.21. The disclosure for this sale can be found here. Insiders have sold 107,547 shares of company stock valued at $5,075,301 in the last 90 days. 27.80% of the stock is currently owned by company insiders.
Amphastar Pharmaceuticals Profile
Amphastar Pharmaceuticals, Inc, a bio-pharmaceutical company, develops, manufactures, markets, and sells generic and proprietary injectable, inhalation, and intranasal products in the United States, China, and France. The company operates through two segments, Finished Pharmaceutical Products and Active Pharmaceutical Ingredient (API).
Featured Articles
- Five stocks we like better than Amphastar Pharmaceuticals
- What is a Bond Market Holiday? How to Invest and Trade
- Alibaba Explodes On Earnings, Inching Toward Triple Digit Prices
- 5 Top Rated Dividend Stocks to Consider
- Is It Time To Game The Roblox Market?
- 3 Stocks to Protect Your Portfolio from the Coronavirus Contagion
- 2 Cheap Stocks The Insiders Are Buying
Receive News & Ratings for Amphastar Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Amphastar Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.
